Oral calcium fosfomycin: Pharmacokinetic/pharmacodynamic study

• Alarcia Lacalle, A ^{[1] [3]} ; Isla, A ^{[1] [3]} ; Solinís, MA ^{[1] [3]} ; Abajo, Z ^[2] ; Cabero Zamorano, M ^[2] ; Canut, A ^{[3] [4]} ; Rodríguez Gascón, A ^{[1] [3]}
  1. [1] Universidad del País Vasco/Euskal Herriko Unibertsitatea

     Universidad del País Vasco/Euskal Herriko Unibertsitatea

     Leioa, España

     
  2. [2] Bioraba Health Research Institute, Clinical Trials Unit, Vitoria-Gasteiz, Spain
  3. [3] Bioaraba, Microbiology, Infectious Diseases, Antimicrobials and Gene Therapy Research Group, VitoriaGasteiz, Spain
  4. [4] Microbiology Service. Araba University Hospital. Vitoria-Gasteiz, Spain.

  Mostrar afiliaciones +
• Localización: RESCIFAR Revista Española de Ciencias Farmacéuticas, ISSN-e 2660-6356, Vol. 2, Nº. 2, 2021 (Ejemplar dedicado a: XV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE FARMACIA INDUSTRIA Y GALÉNICA), págs. 76-78
• Idioma: español
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Urinary tract infections (UTIs) are some of the most common bacterial infections, affecting 150 million people each year worldwide. Calcium fosfomycin is an antimicrobial agent with indication for the treatment of uncomplicated UTIs, being Escherichia coli the most frequently isolated microorganism. EUCAST clinical breakpoint of oral fosfomycin for E. coli in uncomplicated UTI is 8 mg/L, and the epidemiologic cutoff (ECOFF) for E. coli is 4 mg/L. Urinary drug concentrations are correlated with antibacterial activity in uncomplicated UTI infections. Indeed, high urinary antimicrobial concentrations are essential for efficacy. Therefore, the objective of this study was to analyze the urine concentrations of fosfomycin after oral administration to healthy women at different dosing levels from a pharmacokinetic/ pharmacodynamic (PK/PD) point of view.